MARUCCI, Gabriella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.460
EU - Europa 8.402
AS - Asia 5.451
SA - Sud America 749
AF - Africa 99
Continente sconosciuto - Info sul continente non disponibili 72
OC - Oceania 14
Totale 31.247
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.947
CN - Cina 2.483
RU - Federazione Russa 1.848
PL - Polonia 1.527
SG - Singapore 1.508
IT - Italia 1.296
DE - Germania 1.087
BR - Brasile 634
GB - Regno Unito 546
UA - Ucraina 505
SE - Svezia 499
HK - Hong Kong 446
CA - Canada 442
FR - Francia 377
FI - Finlandia 281
TR - Turchia 236
KR - Corea 207
VN - Vietnam 189
IE - Irlanda 118
IN - India 89
BE - Belgio 79
EU - Europa 71
JP - Giappone 70
AR - Argentina 58
MX - Messico 50
NL - Olanda 44
CZ - Repubblica Ceca 41
ZA - Sudafrica 39
BD - Bangladesh 33
IR - Iran 31
ES - Italia 30
AT - Austria 22
RO - Romania 22
EC - Ecuador 19
IQ - Iraq 18
AE - Emirati Arabi Uniti 16
PK - Pakistan 16
CH - Svizzera 13
ID - Indonesia 13
KE - Kenya 12
MA - Marocco 12
RS - Serbia 12
JO - Giordania 11
LT - Lituania 11
TW - Taiwan 11
PE - Perù 10
AU - Australia 9
IL - Israele 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
AZ - Azerbaigian 8
CO - Colombia 8
EG - Egitto 8
PY - Paraguay 8
TN - Tunisia 8
BG - Bulgaria 6
HR - Croazia 6
AM - Armenia 5
GR - Grecia 5
LB - Libano 5
VE - Venezuela 5
AL - Albania 4
BY - Bielorussia 4
CL - Cile 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
GE - Georgia 4
HN - Honduras 4
PH - Filippine 4
CI - Costa d'Avorio 3
KZ - Kazakistan 3
NI - Nicaragua 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
OM - Oman 3
TH - Thailandia 3
CR - Costa Rica 2
ET - Etiopia 2
KH - Cambogia 2
KW - Kuwait 2
LV - Lettonia 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AS - Samoa Americane 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GD - Grenada 1
GM - Gambi 1
Totale 31.230
Salva come PNG Salva come JPEG
Città #
Fairfield 1.492
Woodbridge 1.482
Dallas 1.303
Jacksonville 1.207
Warsaw 1.181
Ashburn 1.162
Chandler 948
Houston 809
Ann Arbor 709
Wilmington 687
Singapore 653
Seattle 634
Cambridge 543
Boardman 509
Hong Kong 427
Nanjing 407
Beijing 386
Kraków 331
Toronto 291
Los Angeles 248
Camerino 235
The Dalles 235
Istanbul 190
Columbus 186
San Mateo 185
Seoul 182
Düsseldorf 178
Tongling 167
Lawrence 163
Princeton 163
Dearborn 158
New York 148
Ogden 136
Moscow 133
Nanchang 125
London 122
Lachine 117
Dublin 116
Buffalo 114
Shanghai 107
Munich 105
Helsinki 104
Milan 95
Kunming 86
Guangzhou 84
Chicago 80
Brussels 75
San Diego 75
Council Bluffs 69
São Paulo 69
Shenyang 66
Tianjin 63
Jiaxing 62
Hebei 61
Santa Clara 60
Ho Chi Minh City 58
Tokyo 56
Hangzhou 45
Hanoi 40
Wuhan 39
Centro 37
Philadelphia 36
Venezia 36
Changsha 35
Ningbo 35
Denver 33
Frankfurt am Main 33
Rome 33
Orem 32
Dong Ket 31
Hefei 31
Redwood City 30
Turku 29
Brno 28
Brooklyn 28
Jinan 27
San Francisco 27
Poplar 26
Venice 26
Orange 25
Stockholm 25
Chennai 24
Johannesburg 24
Norwalk 24
Perugia 24
Phoenix 24
Falls Church 23
Bremen 22
Yiwu 22
Nürnberg 21
Verona 21
Atlanta 20
Boston 20
Nuremberg 20
Zhengzhou 20
Belo Horizonte 19
Montreal 18
Rio de Janeiro 18
St Petersburg 18
Tampa 18
Totale 21.004
Salva come PNG Salva come JPEG
Nome #
1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: Structure-affinity/activity relationship at α1-adrenoceptor subtypes and at 5-HT1A receptors. 580
1,2,4-Benzothiadiazine derivatives as alpha1 and 5-HT1A receptor ligands 559
“1,3 Oxathiolane Muscarinic Ligands Modified at the Cationic Head”. 522
1,3-Dioxolane-based ligands as a novel class of alpha(1)-adrenoceptor antagonists 499
1,3-Dioxolane-based ligands as rigid analogues of Naftopidil: structure-affinity/activity relationships at alpha1 and 5-HT1A receptors. 489
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 404
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 382
Overview on Radiolabel-Free in Vitro Assays for GPCRs 378
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 353
Pharmacological characterization of the GPR17 receptor dual profile 352
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 340
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 325
The G Protein-Coupled Receptor GPR17: Overview and Update 323
GPR17 receptor modulators and their therapeutic implications: review of recent patents 277
“Synthesis and α-Adrenoreceptor Blocking Properties of Phenoxybenzamine-Related (2-Chloroethyl)-(2,3-dihydrobenzo-[1,4] dioxin-2-ylmethyl)-(2-phenoxyethyl) Amines”. 272
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 271
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 261
Synthesis and pharmacological profile of a series of 1-substituted-2-carbonyl derivatives of diphenidol: novel M4 muscarinic receptor antagonists 259
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in Δ16HER2 transgenic mice 257
4-(4-Fluorobenzoyl)-1-[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]piperidine and its derivatives: synthesis and affinity at 5-HT2A, 5-HT2B and 5-HT2c serotonin receptors 251
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 251
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 251
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 248
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 247
Synthesis and antimuscarinic activity of derivatives of 2-substituted-1,3-dioxolanes 238
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 235
“New Pyridazinones: Synthesis and Correlation Between Structure and α-Blocking Activity”. 231
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 231
Synthesis and alpha1-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin 229
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 225
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 221
5HT2B receptor antagonists: a probe for spotting the pharmacophore 215
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 212
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 211
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 211
Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor 211
Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications. 209
New sensible method to quantize the intestinal absorption of receptor ligands 208
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 207
Benzimidazole, benzoxazole and benzothiazole derivatives as 5HT(2B) receptor ligands. Synthesis and preliminary pharmacological evaluation 206
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 206
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 206
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 201
(+)-Cyclazosin derivatives as α1-adrenoceptor antagonists 200
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 200
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 199
Antiviral properties of deazaadenine nucleoside derivatives 199
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 198
Determination of Muscarinic Agonist Potencies at M1 and M2 Muscarinic Receptors in a Modified Pithed rat Preparation 197
(+)-Cyclazosin, a selective alpha1B-adrenoceptor antagonist: Functional evaluation in rat and rabbit tissues 196
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 195
Simplified analogues of Ritanserin and their affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors 195
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 195
(2,2-Diphenyl-[1,3]oxathiolan-5-ylmethyl)-(3-phenyl-propyl)-amine: a Potent and Selective 5-HT1A Receptor Agonist 195
"[4-[[N-(3-Chlorophenyl)carbamoyl]-2-butynyl]-trimethylammonium (McN-A-343)-Related Compounds. Effect of the Butynyl Chain Inclusion into an Aromatic Unit of the Potency for Muscarinic Receptors 194
Analogues of Prazosin That Bear a Benextramine-Related Polyamine Backbone Exhibit Different Antagonism toward alpha1-Adrenoceptor Subtypes 193
Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine 193
Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 3. Effect of inserting the tetraamine backbone into a macrocyclic structure 192
Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives 192
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 192
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 192
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 191
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 191
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 191
Synthesis and pharmacological characterization of enantiomerically pure muscarinic agonists: difluoromuscarines 190
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 189
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 188
Chiral analogues of (+)-cyclazosin as potent α1B-adrenoceptor selective antagonist 188
Adenosine receptor modeling: what does the A2A crystal structure tell us? 187
Structure-Activity Relatioships Among Novel Phenoxybenzamine-Related Beta-Chloroethylamines. 187
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 186
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 186
Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds 185
“Dialkylaminoalkyl Esters of 2,2 Diphenyl-2-Alkylthioacetic Acids: A New Class of Potent and Functionally Selective Muscarinic Antagonists”. 185
Synthesis and antagonistic activity at muscarinic receptor subtypes of some derivatives of diphenidol 184
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 184
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 184
“N,N-diethylaminoethanol and N-methyl-4-piperidinol Esters of 2,2-diphenyl-2-Ethylthioacetic Acid as Potent and Selective Muscarinic Antagonist”. 183
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 183
Synthesis and α1-antagonist activity of derivatives of 4-chloro-5-{4-[2-(2-methoxyphenoxy)-ethyl]-1-piperazinyl}-3(2H)-pyridazinone 183
“Pharmacological Characterization of Muscarinic Receptor Subtypes in Rabbit Isolated Tissue Preparations” 176
Synthesis and pharmacological characterization of chiral pyrrolidinylfuran derivatives: The discovery of new functionally selective muscarinic agonists 176
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 176
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure 175
“Synthesis and Pharmacological Evaluation of Enantiomerically Pure 4-Deoxy-4-Fluoro-Muscarines”. 175
Molecular modulation of muscarinic antagonists. Synthesis and affinity profile of 2,2-diphenyl-2-ethylthio-acetic acid esters designed to probe the binding site cavity. 174
“Synthesis and Pharmacological Activity of Some New Pyridazinones”. 173
“Synthesis and α1-Antagonist Activity of New Prazosin-and Benextramine-Related Tetraamine Disulfides”. 173
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 172
Structure-affinity/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at α1 and 5-HT1A receptors 172
Molecular modulation of muscarinic antagonists. Synthesis and pharmacological profile of 2,2-diphenyl-2-ethylthioacetic and 3,3-diphenyl-3-ethylthiopropionic acid derivatives characterized by a dipeptide spacer. 170
Synthesis and pharmacological characterization of new chiral derivatives of muscarine and allo-muscarine 169
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 168
“Novel and Highly Selective Postsynaptic α-Adrenoreceptor Antagonists: Synthesis and Structure-Activity Relationships of Alkane-Bridged [4-(phenoxyethyl)-1-piperazinyl]-3 (2H)-pyridazinones”. 168
Structure-Activity Relationships of Methoctramine-Related Polyamines as Muscular Nicotinic Receptor Noncompetitive Antagonists. 2. Role of Polymethylene Chain Lengths Separating Amine Functions and of Substituents on the Terminal Nitrogen Atoms. 168
Searching for cyclazosin analogues as alfa1B-adrenoceptor antagonists 167
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 164
Highly chiral muscarinic ligands: The discovery of (2S,2 ' R,3 ' S,5 ' R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M-2 partial agonist 164
SAR Studies on the Potent and Selective Muscarinic Antagonist 2-Ethylthio-2,2-diphenylacetic Acid N,N-Diethylaminoethyl Ester 164
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 163
Totale 22.933
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.504 0 0 0 0 0 362 629 95 318 188 556 356
2021/20221.977 189 478 39 103 99 65 100 154 145 228 147 230
2022/20232.322 257 120 84 384 260 312 13 146 385 121 170 70
2023/20241.769 252 102 112 59 71 115 86 103 198 70 63 538
2024/20255.716 203 146 485 264 159 340 639 1.449 429 403 399 800
2025/20265.190 534 593 1.706 1.137 959 261 0 0 0 0 0 0
Totale 31.728